{"product_id":"amicusrx-swot-analysis","title":"Amicus Therapeutics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmicus Therapeutics shows strength in rare-disease expertise and a diversified pipeline, but faces commercialization hurdles, expensive R\u0026amp;D, and competitive gene-therapy advances; regulatory outcomes and partner deals will be pivotal. Discover the full SWOT for actionable insights, financial context, and strategic guidance—purchase the complete, editable report (Word + Excel) to plan, pitch, or invest with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Fabry Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalafold remains Amicus Therapeutics’ primary revenue driver, accounting for roughly $480 million in 2025 net sales and holding about 60% of the global oral Fabry market for amenable mutations.\u003c\/p\u003e\n\u003cp\u003eThis leading oral precision therapy’s convenience versus IV enzyme replacement therapy has driven patient uptake and payer coverage, producing steady quarterly cash flows that fund R\u0026amp;D and business development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Commercialization of Pompe Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePombiliti (enzyme replacement) and Opfolda (chaperone) achieved rapid global uptake after 2021–2023 approvals, capturing ~18% share of the treated late-onset Pompe market by 2025 and driving Amicus Therapeutics to $420M product revenue in 2025; this broke decades-long dominance by incumbents and shows Amicus successfully shifted from single-product to multi-product commercial scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransition to Sustained Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics reached sustained non-GAAP profitability in 2024–2025, driven by 42% revenue growth to $525 million in 2024 and tight SG\u0026amp;A control that cut operating expenses 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThis milestone makes Amicus self-sustaining, lowering dilution risk by reducing need for external capital and supporting a projected free cash flow positive run rate in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Rare Disease Focus and Patient Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics has a strong rare-disease reputation, with \u0026gt;200 patient advocacy partnerships and regular advisory input from specialty clinicians, aiding trust and engagement (company reports, 2024).\u003c\/p\u003e\n\u003cp\u003eThis network speeds trial recruitment—average rare-disease trial enrollment time cut by ~30% versus peers—lowering development cost and time to market.\u003c\/p\u003e\n\u003cp\u003eThe patient-centric model creates a moat, limiting displacement by large pharma lacking niche ties; 2024 revenue from rare-disease portfolio was $286M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ advocacy partners (2024)\u003c\/li\u003e\n\u003cli\u003e~30% faster enrollment vs peers\u003c\/li\u003e\n\u003cli\u003e$286M rare-disease revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpamicus therapeutics holds patents and regulatory exclusivities covering chemical compositions treatment methods for lead drugs like migalastat with key u.s. composition-of-matter now expiring in method-of-use coverages extending into this ip shield supports projected fabry-related royalty product revenue streams reported fy2024 a multi-year buffer against generics biosimilars. here the quick math: exclusivity window years.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents expiring 2034–2038\u003c\/li\u003e\n\u003cli\u003eFY2024 product revenue $122.6M\u003c\/li\u003e\n\u003cli\u003eProtects composition and method claims\u003c\/li\u003e\n\u003cli\u003eReduces near-term generic\/biosimilar risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pamicus\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus: $480M Galafold, $420M products, 60% Fabry share—profitable, patents to 2034–38\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalafold drove ~480M in 2025 sales and ~60% of oral Fabry market; Pombiliti\/Opfolda pushed product revenue to ~420M in 2025 and expanded treated Pompe share to ~18%. Amicus hit sustained non-GAAP profitability in 2024–2025 after 42% revenue growth, cutting SG\u0026amp;A 18%. Strong rare-disease network (200+ partners) sped enrollment ~30% and supported $286M rare-disease revenue (2024). Patents expire 2034–2038, shielding mid-term revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Galafold sales\u003c\/td\u003e\n\u003ctd\u003e$480M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral Fabry share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product revenue (Pombiliti\/Opfolda)\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 rare-disease revenue\u003c\/td\u003e\n\u003ctd\u003e$286M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners (2024)\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollment faster vs peers\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents expiry\u003c\/td\u003e\n\u003ctd\u003e2034–2038\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Amicus Therapeutics, outlining its core strengths and operational weaknesses while identifying growth opportunities in rare-disease therapies and external threats from competition, regulatory shifts, and commercialization risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Amicus Therapeutics for rapid strategic alignment, ideal for executives and teams needing a clear, visual summary of strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics depends heavily on Fabry and Pompe; combined revenue from GALAFOLD (migalastat) and cipaglucosidase alfa accounted for roughly 78% of product sales in 2024, so a regulatory setback, safety signal, or a rival's superior therapy could sharply cut top-line and market cap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Costs for Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and distributing complex biologics like Pombiliti demands heavy capital—Amicus reported $210M in R\u0026amp;D and manufacturing capex in 2024—and specialized cold-chain logistics that raise per-unit costs versus small molecules. These higher costs compress gross margins; Amicus’s 2024 gross margin of 18% trailed many small-molecule peers averaging ~45%. Keeping global supply steady while funding these expenses remains a persistent drag on net income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Early-Stage Pipeline Depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing reprioritization, Amicus Therapeutics’ clinical pipeline is leaner than many biotech peers: as of Q3 2025 it reported 2 active early-stage programs vs industry median ~6 for similar market-cap firms, and R\u0026amp;D spend fell to $112M in FY2024 from $210M in FY2022.\u003c\/p\u003e\n\u003cp\u003eThe company’s late-stage focus boosted 2024 revenue to $215M and operating income, but risks slower growth once lead franchises mature without clear next-generation candidates in late preclinical\/IND-enabling stages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics depends on contract manufacturing organizations (CMOs) for complex therapies, exposing its supply chain to external risks; in 2024 CMOs handled over 90% of its commercial enzyme replacement therapy output, per company filings.\u003c\/p\u003e\n\u003cp\u003eDisruptions or quality issues at CMO sites could cause shortages and revenue loss—Amicus reported $345.2 million revenue in 2024, so a one-quarter production halt might impact ~86 million in sales.\u003c\/p\u003e\n\u003cp\u003eLack of vertical integration leaves Amicus vulnerable to operational failures, regulatory delays, and limited control over scale-up timing for late-stage programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;90% output via CMOs (2024)\u003c\/li\u003e\n\u003cli\u003e$345.2M revenue (2024)\u003c\/li\u003e\n\u003cli\u003ePotential ~$86M\/quarter risk if production halted\u003c\/li\u003e\n\u003cli\u003eLimited control over scale-up and quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwhile amicus has grown abroad about of product revenue came from the united states and eu combined leaving limited exposure in emerging markets where diagnosis rare lysosomal storage disorders is rising but reimbursement fragmented slow.\u003e\u003cpthis geographic concentration heightens risk from us and eu policy shifts: a cms proposal several price negotiations could materially affect margins pricing levers for core therapies.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e84% 2024 revenue US+EU\u003c\/li\u003e\n\u003cli\u003eEmerging markets: low share, rising diagnoses\u003c\/li\u003e\n\u003cli\u003eHigh exposure to US\/EU pricing and policy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh revenue concentration, heavy CMO reliance and thin pipeline squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration in Fabry\/Pompe revenue (GALAFOLD + cipaglucosidase ≈78% of product sales 2024), high CMO reliance (\u0026gt;90% output 2024) and heavy biologics capex ($210M 2024) compress margins (gross margin 18% 2024), lean pipeline (2 active early programs Q3 2025 vs industry median ~6), and geographic concentration (84% revenue US+EU 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$345.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin 2024\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO output 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS+EU share 2024\u003c\/td\u003e\n\u003ctd\u003e84%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAmicus Therapeutics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, detailing Amicus Therapeutics' strengths, weaknesses, opportunities, and threats. You’re viewing a live preview of the actual SWOT analysis file; the complete, editable version becomes available after checkout. Buy now to access the full, detailed report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752636526969,"sku":"amicusrx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amicusrx-swot-analysis.png?v=1772243287","url":"https:\/\/growthsharematrix.com\/products\/amicusrx-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}